Molecular Profile | KRAS G12D TP53 S127Y |
Therapy | Dasatinib + Demcizumab |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KRAS G12D TP53 S127Y | lung adenocarcinoma | sensitive | Dasatinib + Demcizumab | Preclinical - Pdx | Actionable | In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149). | 26855149 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26855149) | Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. | Full reference... |